Shilpa Medicare Ltd
Shilpa Medicare Secures Third Major International Mandate with NXI Therapeutics š
- Shilpa Medicare Limited (SML) has entered into a binding agreement with Switzerland-based NXI Therapeutics AG for the development and supply of a New Chemical Entity (NCE).
- The agreement covers development, manufacturing, and commercial supply of a novel asset targeting autoimmune and alloimmune disorders.
- SML will provide CMC development, process scale-up, GMP clinical supply, and long-term commercial manufacturing support.
- This is SML's third major international mandate in recent months, enhancing its role as a strategic innovation partner for global biotech companies.
- The agreement includes milestone-linked expansion potential and may evolve into a multi-year commercial supply relationship based on clinical and regulatory success.
- The collaboration is expected to strengthen SML's capabilities in innovative therapies and support growth in high-value biologics and specialty therapeutics segments.
- NXI Therapeutics AG is not a related party to SML or its promoters, ensuring an arm's length transaction.